• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Corvex Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    7/7/26 5:10:57 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    false --12-31 0001734750 0001734750 2026-07-01 2026-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 1, 2026

     

    CORVEX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40254   82-4233771
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    3401 North Fairfax Drive, Suite 3230,

    Arlington, Virginia

      22226
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (866) GET-GPUS ((866) 438-4787)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   MOVE  

    The Nasdaq Stock Market LLC

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

      

     

     

     

     

     

    Item 3. 02 Unregistered Sales of Equity Securities.

     

    The disclosure under Item 8.01 below is incorporated by reference into this Item 3.02.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    As previously disclosed, on March 19, 2026, Corvex, Inc. (the “Company”) acquired Corvex Legacy Holdings, Inc. (formerly known as Corvex, Inc.) (“Corvex OpCo”), in accordance with the terms of the Amended and Restated Agreement and Plan of Merger, dated March 19, 2026 (the “Merger Agreement”), by and among the Company, Thor Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Corvex OpCo. Pursuant to the Merger Agreement, Merger Sub merged with and into Corvex OpCo, pursuant to which Corvex OpCo was the surviving corporation and became a wholly owned subsidiary of the Company (the “Merger”). 

     

    Appointment of Seth Demsey as co-Chief Executive Officer

     

    On July 1, 2026, as previously disclosed and pursuant to the terms of the Merger Agreement, Seth Demsey was appointed co-Chief Executive Officer of the Company, alongside Jay Crystal, effective following the Annual Meeting (as defined below). 

     

    Mr. Demsey, age 49, has served as a member of the Company’s board of directors since March 19, 2026. Mr. Demsey has served as the Co-Chief Executive Officer and Co-Founder of Corvex OpCo and on the Corvex OpCo board of directors since October 2024. Before joining Corvex OpCo, Mr. Demsey served as the chief executive officer and co-founder of Configure8 from May 2021 through October 2024. He has spent nearly three decades architecting and operating high-impact AI/ML and developer platforms across startups and industry leaders including NASA, Microsoft, Google, and AOL/Yahoo!. He holds dozens of patents spanning high-performance computing, distributed systems, security, and data management. Prior to co-founding Corvex OpCo, Mr. Demsey served in technical leadership roles driving innovation in large-scale distributed computing and mission-critical infrastructure. His expertise encompasses the full stack of cloud infrastructure technologies required to deliver reliable, high-performance AI computing at scale. Mr. Demsey received a Bachelor of Science degree in Computer Engineering from Bucknell University and was previously a business fellow at The Wharton School of the University of Pennsylvania. 

     

    Pursuant to the Merger Agreement, on March 19, 2026, the Company entered into an Employment Agreement with Mr. Demsey. A description of the terms and conditions of Mr. Demsey’s Employment Agreement is set forth in Item 5.02 of the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission on March 19, 2026 (the “March 19 Form 8-K”), which such description is incorporated by reference herein. Such description of Mr. Demsey’s Employment Agreement does not purport to be complete and is qualified in its entirety by reference to Mr. Demsey’s Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    1

     

     

    Approval of Corvex, Inc. 2026 Equity Incentive Plan

     

    On July 1, 2026, the stockholders of the Company approved the Corvex, Inc. 2026 Equity Incentive Plan (the “2026 Plan”).  A description of the terms and conditions of the 2026 Plan is set forth in the Company’s Proxy Statement for the 2026 Annual Meeting of Stockholders of the Company that was commenced on June 26, 2026, adjourned, and reconvened on July 1, 2026 (the “Annual Meeting”), as filed with the Securities and Exchange Commission on June 5, 2026 (the “Annual Meeting Proxy Statement”) under the heading “Proposal 5 – The 2026 Plan Proposal”, which such description is incorporated by reference herein.  This summary does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the 2026 Plan, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Approval of Corvex, Inc. 2026 Employee Stock Purchase Plan

     

    On July 1, 2026, the Company’s stockholders approved the Corvex, Inc. 2026 Employee Stock Purchase Plan (the “ESPP”) at the Annual Meeting. A description of the terms and conditions of the ESPP is set forth in the Annual Meeting Proxy Statement under the heading “Proposal 6 – The 2026 ESPP Proposal”, which such description is incorporated by reference herein. This summary does not purport to be complete and is subject to, and qualified in its entirety, by the full text of the ESPP, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    Amendment to Series D Preferred Stock

     

    As previously disclosed, in connection with the Merger the Company issued shares of Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”) and Series D Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series D Preferred Stock”) to the former security holders of Corvex OpCo. Certain holders of Series C Preferred Stock (the “Exchanging Stockholders”) expressed interest in exchanging their shares of Series C Preferred Stock for Series D Preferred Stock before the Annual Meeting. On July 1, 2026, the Company entered into exchange agreements with the Exchanging Stockholders to accommodate these requests (the “Preferred Exchange”). 

     

    In connection with the Preferred Exchange, the Company filed a Certificate of Increase with the Secretary of State of the State of Delaware to increase the number of authorized shares of Series D Preferred Stock to 50,000 shares (the “Certificate of Increase”). The Certificate of Increase did not otherwise amend the Certificate of Designations for the Series D Preferred Stock.

     

    The foregoing description of the Certificate of Increase does not purport to be complete and is qualified in its entirety by reference to the Certificate of Increase, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    2

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On July 1, 2026, the Company reconvened the Annual Meeting that was commenced on June 26, 2026 and adjourned until July 1, 2026. The certified results of each of the matters voted upon at the Annual Meeting, which are more fully described in the Annual Meeting Proxy Statement, follow.

     

    The Company’s stockholders elected two nominees to the Company’s Board of Directors (the “Board”) to serve for three-year terms as Class II directors and one nominee to the Board to serve for a one-year term as a Class III director, with votes cast as follows:

     

    Director Name  For   Withheld   Broker
    Non-Votes
     
    Jay Crystal, Class II Director   756,080    184    664,331 
    Patrick Fleury, Class II Director   756,080    184    664,331 
    Nicholas Donofrio, Class III Director   752,073    4,191    664,331 

     

    The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(a) and 5635(b), the issuance of more than 20% of the Company’s issued and outstanding common stock in connection with the conversion of shares of Series C Preferred Stock and Series D Preferred Stock pursuant to the Merger Agreement (the “Conversion Proposal”), with votes cast as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    605,849   1,326    1,024    664,331 

     

     

    The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(a) and 5635(b), the issuance of more than 20% of the Company’s issued and outstanding common stock in connection with the vesting of restricted stock units and exercise of options issued and outstanding prior to the Merger pursuant to the Merger Agreement, with votes cast as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    605,237   1,803    1,159    664,331 

     

    The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for 2026, with votes cast as follows:

     

     For  Against   Abstain   Broker Non-Votes 
    1,418,132   1,131    1,332    -- 

     

    The Company’s stockholders approved the 2026 Plan and the awards described in the New Plan Benefits table, the issuance of which are subject to the approval of the 2026 Plan, with votes cast as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    731,164   23,323    1,777    664,331 

     

    The Company’s stockholders approved the ESPP, with votes cast as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    745,067   9,567    1,630    664,331 

     

     The Company’s stockholders approved the adjournment of the Annual Meeting to permit further solicitation of proxies, if necessary or appropriate, with votes cast as follows:

     For  Against   Abstain   Broker Non-Votes 
    1,416,097   2,113    2,385    664,331 

     

    3

     

     

    Item 8.01 Other Events.

     

    Following the Annual Meeting and stockholder approval of the Conversion Proposal, on July 7, 2026, all outstanding shares of Series C Preferred Stock automatically converted into shares of the Company’s common stock in accordance with the Certificate of Designations for the Series C Preferred Stock. Additionally, on July 7, 2026, the Company effected the conversion shares of Series D Preferred Stock representing 4,752,244 shares of common stock into common stock pursuant to conversion notices submitted by holders of Series D Preferred Stock. Following such conversions, the Company has 27,635,745 shares of common stock outstanding and shares of Series D Preferred Stock convertible into 28,929,592 shares of common stock.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibits

     

    The following exhibits are filed herewith:

     

    Exhibit No.   Exhibit Description
         
    3.1   Certificate of Increase of Series D Non-Voting Convertible Preferred Stock
    10.1   Employment Agreement between the Company and Seth Demsey (previously filed as Exhibit 10.5 to the Company’s Current Report on Form 8-k filed on March 19, 2026, which is incorporated herein by reference)
    10.2   Corvex, Inc. 2026 Equity Incentive Plan (previously filed as Exhibit 4.12 to the Company’s Form S-8 (File No. 333-297203) filed on July 1, 2026, which is incorporated herein by reference)
    10.3   Corvex, Inc. 2026 Employee Stock Purchase Plan (previously filed as Exhibit 4.15 to the Company’s Form S-8 (File No. 333-297203) filed on July 1, 2026, which is incorporated herein by reference)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CORVEX, INC.
         
    Date: July 7, 2026 By: /s/ Chance Moreland
        Chance Moreland
        Chief Financial Officer

     

    5

    Get the next $MOVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Co-Chief Executive Officer Crystal John Adler Iii converted options into 4,053,677 shares, increasing direct ownership by 109% to 6,414,723 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:04 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fairbairn Emily converted options into 1,205,282 shares (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:30:26 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/12/24 4:30:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:08 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MOVE
    SEC Filings

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    SEC Form S-1 filed by Corvex Inc.

    S-1 - Corvex, Inc. (0001734750) (Filer)

    7/10/26 5:10:53 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Corvex, Inc. (0001734750) (Filer)

    7/7/26 5:10:57 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by Corvex Inc.

    S-8 - Corvex, Inc. (0001734750) (Filer)

    7/1/26 4:58:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Leadership Updates

    Live Leadership Updates

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    SC 13G/A - Movano Inc. (0001734750) (Subject)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:20:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Financials

    Live finance-specific insights

    View All

    Corvex Reports Q1 2026 Financial Results and Provides Business Update

    Conference Call at 4:30 PM ET / 1:30 PM PTARLINGTON, Va., May 19, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, reported first quarter 2026 results and provided a business update. Reported Q1'26 Highlights:Completed acquisition of Corvex OpCo on March 19, 2026, transitioning the Company's primary business to AI cloud computing and renaming Movano Inc. to Corvex, Inc., effective March 23, 2026.Including 12 days of Corvex OpCo operations in the period, Q1'26 total revenue w

    5/19/26 4:06:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex to Host First Quarter 2026 Earnings Call on Tuesday, May 19, 2026

    Conference Call at 4:30 PM ET/ 1:30 PM PTARLINGTON, Va., May 11, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced that it will hold its first quarter 2026 earnings call on Tuesday, May 19, 2026 at 4:30 pm ET / 1:30 pm PT. Management will host a conference call and live audio webcast to discuss first quarter 2026 results and provide a business update. The live webcast of the earnings conference call can be accessed at the Corvex Investor Relations website at i

    5/11/26 8:30:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CORVEX, INC. ANNOUNCES ADDITIONAL DETAILS OF SPECIAL 35.8% STOCK DIVIDEND FOR SHAREHOLDERS OF RECORD ON MARCH 30, 2026

    ARLINGTON, Va., March 24, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE) ("Corvex" or the "Company") today announced additional details regarding the special 35.8% stock dividend (the "Stock Dividend") previously announced on March 19, 2026.  Each stockholder of record as of the close of business on March 30, 2026 will be entitled to receive a 35.8% stock dividend at no cost and with no action required on the part of the stockholder.For example, a stockholder holding 10,000 shares of Corvex common stock, par value $0.0001 per share (the "Common Stock") as of the close of tradin

    3/24/26 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care